Neoadjuvant combination treatment with checkpoint inhibitors, chemotherapy, and BRAF/MEK inhibitors for BRAFV600E glioblastoma results in sustained response: A case report

被引：0
作者：
Wagle, Naveed [1 ]
Sharma, Akanksha [1 ]
Nguyen, Minhdan [1 ]
Truong, Judy [1 ]
Juarez, Tiffany M. [1 ,2 ]
Kesari, Santosh [1 ]
机构：
[1] St Johns Canc Inst, Pacific Neurosci Inst, Providence St Johns Hlth Ctr, St Monica, CA USA
[2] Cure Sci Inst, San Diego, CA USA
来源：
NEURO-ONCOLOGY ADVANCES | 2024年 / 6卷 / 01期
关键词：
BRAFV600E; case report; checkpoint inhibitors; glioblastoma; neoadjuvant; BRAIN METASTASES; OPEN-LABEL; MELANOMA; PSEUDOPROGRESSION; NIVOLUMAB; GRADE; MULTICENTER; IPILIMUMAB; PHASE-2;
D O I：
10.1093/noajnl/vdae110
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Radiation's confounding and adverse effects on tumor microenvironment and normal brain could potentially be delayed by upfront combination treatment. We present a patient with newly diagnosed BRAF(V600E)-mutant, PD-L1-positive glioblastoma treated with off-label RAF/MEK inhibitors encorafenib/binimetinib after progressing on postoperative immune checkpoint blockade and temozolomide (no radiation administered: NCT03425292). Complete response occurred 6 months after adding encorafenib/binimetinib, and clinical benefit was sustained for over 20 months. Treatment was well tolerated with manageable toxicities, with quality of life and cognitive function maintained throughout treatment. Adding encorafenib/binimetinib to immunotherapy and temozolomide conferred favorable and lasting efficacy for our BRAF(V600E)-mutant glioblastoma patient, justifying future studies.
引用
收藏
页数：4
相关论文
共 26 条
  • [1] US Food and Drug Administration Approval Summary: Nivolumab Plus Platinum-Doublet Chemotherapy for the Neoadjuvant Treatment of Patients With Resectable Non-Small-Cell Lung Cancer
    Akinboro, Oladimeji
    Drezner, Nicole
    Amatya, Anup
    Runyan, Jin
    Fourie-Zirkelbach, Jeanne
    Zhao, Miao
    Bi, Youwei
    Korsah, Kwadwo
    Mixter, Bronwyn
    Tang, Shenghui
    Larkins, Erin
    Pazdur, Richard
    Beaver, Julia A. A.
    Singh, Harpreet
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17) : 3249 - +
  • [2] Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma
    Bouffet, Eric
    Geoerger, Birgit
    Moertel, Christopher
    Whitlock, James A.
    Aerts, Isabelle
    Hargrave, Darren
    Osterloh, Lisa
    Tan, Eugene
    Choi, Jeea
    Russo, Mark
    Fox, Elizabeth
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (03) : 664 - +
  • [3] Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
    Bouffet, Eric
    Larouche, Valerie
    Campbell, Brittany B.
    Merico, Daniele
    de Borja, Richard
    Aronson, Melyssa
    Durno, Carol
    Krueger, Joerg
    Cabric, Vanja
    Ramaswamy, Vijay
    Zhukova, Nataliya
    Mason, Gary
    Farah, Roula
    Afzal, Samina
    Yalon, Michal
    Rechavi, Gideon
    Magimairajan, Vanan
    Walsh, Michael F.
    Constantini, Shlomi
    Dvir, Rina
    Elhasid, Ronit
    Reddy, Alyssa
    Osborn, Michael
    Sullivan, Michael
    Hansford, Jordan
    Dodgshun, Andrew
    Klauber-Demore, Nancy
    Peterson, Lindsay
    Patel, Sunil
    Lindhorst, Scott
    Atkinson, Jeffrey
    Cohen, Zane
    Laframboise, Rachel
    Dirks, Peter
    Taylor, Michael
    Malkin, David
    Albrecht, Steffen
    Dudley, Roy W. R.
    Jabado, Nada
    Hawkins, Cynthia E.
    Shlien, Adam
    Tabori, Uri
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (19) : 2206 - +
  • [4] MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients
    Brandes, Alba A.
    Franceschi, Enrico
    Tosoni, Alicia
    Blatt, Valeria
    Pession, Annalisa
    Tallini, Giovanni
    Bertorelle, Roberta
    Bartolini, Stefania
    Calbucci, Fabio
    Andreoli, Alvaro
    Frezza, Giampiero
    Leonardi, Marco
    Spagnolli, Federica
    Ermani, Mario
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) : 2192 - 2197
  • [5] Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
    Cloughesy, Timothy F.
    Mochizuki, Aaron Y.
    Orpilla, Joey R.
    Hugo, Willy
    Lee, Alexander H.
    Davidson, Tom B.
    Wang, Anthony C.
    Ellingson, Benjamin M.
    Rytlewski, Julie A.
    Sanders, Catherine M.
    Kawaguchi, Eric S.
    Du, Lin
    Li, Gang
    Yong, William H.
    Gaffey, Sarah C.
    Cohen, Adam L.
    Mellinghoff, Ingo K.
    Lee, Eudocia Q.
    Reardon, David A.
    O'Brien, Barbara J.
    Butowski, Nicholas A.
    Nghiemphu, Phioanh L.
    Clarke, Jennifer L.
    Arrillaga-Romany, Isabel C.
    Colman, Howard
    Kaley, Thomas J.
    De Groot, John F.
    Liau, Linda M.
    Wen, Patrick Y.
    Prins, Robert M.
    [J]. NATURE MEDICINE, 2019, 25 (03) : 477 - +
  • [6] Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
    Flaherty, Keith T.
    Infante, Jeffery R.
    Daud, Adil
    Gonzalez, Rene
    Kefford, Richard F.
    Sosman, Jeffrey
    Hamid, Omid
    Schuchter, Lynn
    Cebon, Jonathan
    Ibrahim, Nageatte
    Kudchadkar, Ragini
    Burris, Howard A., III
    Falchook, Gerald
    Algazi, Alain
    Lewis, Karl
    Long, Georgina V.
    Puzanov, Igor
    Lebowitz, Peter
    Singh, Ajay
    Little, Shonda
    Sun, Peng
    Allred, Alicia
    Ouellet, Daniele
    Kim, Kevin B.
    Patel, Kiran
    Weber, Jeffrey
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (18) : 1694 - 1703
  • [7] Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
    Goldberg, Sarah B.
    Gettinger, Scott N.
    Mahajan, Amit
    Chiang, Anne C.
    Herbst, Roy S.
    Sznol, Mario
    Tsiouris, Apostolos John
    Cohen, Justine
    Vortmeyer, Alexander
    Jilaveanu, Lucia
    Yu, James
    Hegde, Upendra
    Speaker, Stephanie
    Madura, Matthew
    Ralabate, Amanda
    Rivera, Angel
    Rowen, Elin
    Gerrish, Heather
    Yao, Xiaopan
    Chiang, Veronica
    Kluger, Harriet M.
    [J]. LANCET ONCOLOGY, 2016, 17 (07) : 976 - 983
  • [8] Gutzmer R, 2020, LANCET, V395, P1835, DOI 10.1016/S0140-6736(20)30934-X
  • [9] BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study
    Kaley, Thomas
    Touat, Mehdi
    Subbiah, Vivek
    Hollebecque, Antoine
    Rodon, Jordi
    Lockhart, A. Craig
    Keedy, Vicki
    Bielle, Franck
    Hofheinz, Ralf-Dieter
    Joly, Florence
    Blay, Jean-Yves
    Chau, Ian
    Puzanov, Igor
    Raje, Noopur S.
    Wolf, Jurgen
    DeAngelis, Lisa M.
    Makrutzki, Martina
    Riehl, Todd
    Pitcher, Bethany
    Baselga, Jose
    Hyman, David M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (35) : 3477 - +
  • [10] Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
    Motzer, Robert
    Alekseev, Boris
    Rha, Sun-Young
    Porta, Camillo
    Eto, Masatoshi
    Powles, Thomas
    Gruenwald, Viktor
    Hutson, Thomas E.
    Kopyltsov, Evgeny
    Mendez-Vidal, Maria J.
    Kozlov, Vadim
    Alyasova, Anna
    Hong, Sung-Hoo
    Kapoor, Anil
    Alonso Gordoa, Teresa
    Merchan, Jaime R.
    Winquist, Eric
    Maroto, Pablo
    Goh, Jeffrey C.
    Kim, Miso
    Gurney, Howard
    Patel, Vijay
    Peer, Avivit
    Procopio, Giuseppe
    Takagi, Toshio
    Melichar, Bohuslav
    Rolland, Frederic
    De Giorgi, Ugo
    Wong, Shirley
    Bedke, Jens
    Schmidinger, Manuela
    Dutcus, Corina E.
    Smith, Alan D.
    Dutta, Lea
    Mody, Kalgi
    Perini, Rodolfo F.
    Xing, Dongyuan
    Choueiri, Toni K.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (14) : 1289 - 1300
123